PLRZ — Polyrizon Ltd.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1893645 · Israel
Last close
$14.65
Market Cap
$27.42M
52W High
$17.95
52W Low
$10.36
ADV30
39,244
Next earnings
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 21,437,000 1,306,000 443,000
Jun 2025 18,739,000 15,828,000 364,000
Dec 2024 5,547,000 2,554,000 261,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-8,401,000
Inventory
Receivables
ST Investments
$11,158,000
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -5,785,000 -3,335,000 21,437,000 443,000 -4,528,000
Dec 2024 0 -1,302,000 -1,545,000 5,547,000 261,000 -1,147,000
Dec 2023 0 -635,000 -600,000 559,000 750,000 -537,000
Dec 2022 0 -895,000 -779,000 546,000 1,446,000 -1,132,000

Peers — same industry

TickerNameMarket CapLastDaily %
FOFA FAMILY OFFICE OF AMERICA, INC. $27.32M $0.90
PSTV PLUS THERAPEUTICS, INC. $27.54M $4.00
RGNT REGENTIS BIOMATERIALS LTD. $26.62M $3.79
ARAY ACCURAY INC $28.71M $0.24
GTHP GUIDED THERAPEUTICS INC $28.96M $0.30

News headlines (Yahoo Finance, 1h cache)

Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)
2026-07-02 12:29 · Yahoo
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
2026-07-02 11:32 · Yahoo
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
2026-06-29 12:44 · Yahoo
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
2026-06-17 12:15 · Yahoo
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
2026-06-15 12:05 · Yahoo
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
2026-06-10 11:47 · Yahoo
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
2026-06-08 13:25 · Yahoo
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
2026-05-13 13:25 · Yahoo
Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
2026-05-04 12:45 · Yahoo
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
2026-04-27 13:28 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.